CORT stock forecast
Our latest prediction for Corcept Therapeutics, Inc.'s stock price was made on the May 4, 2017 when the stock price was at 9.74$.
In the short term (2weeks), CORT's stock price should outperform the market by 2.93%. During that period the price should oscillate between -7.28% and +7.99%.
In the medium term (3months), CORT's stock price should outperform the market by 3.75%. During that period the price should oscillate between -16.59% and +24.05%.Get email alerts
About Corcept Therapeutics, Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
At the moment the company generates 238M USD in revenues.
On its last earning announcement, the company reported a profit of 1.21$ per share.
The book value per share is 2.10$
Three months stock forecastMay 4, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|